|
|
|
| |
|
| January 3, 2011
|
|
|
| BioTime to Produce Stem Cells for Research in Muscle Disorders
|
|
|
| December 21, 2011
| |
|
| BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products
| |
|
| December 16, 2011
| |
|
| BioTime's Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-Dx™
| |
|
| Video: OncoCyte CEO Dr. Joseph Wagner Discusses Novel Pan-Cancer Diagnostic Product
| |
|
| December 12, 2011
| |
|
| BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies
| |
|
| November 29, 2011
| |
|
| BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors
| |
|
| November 14, 2011
| |
|
| BioTime Cell Information Now Available in GeneCards®
| |
|
| November 8, 2011
| |
|
| BioTime Announces Third Quarter 2011 Financial Results and Recent Corporate Accomplishments
| |
|
| October 25,2011
| |
|
| BioTime CEO Michael D. West to Present Keynote Address at Translational Strategies for Tissue Engineering Conference
| |
|
| October 13, 2011
| |
|
| BioTime Publishes Paper Describing First Complete Sequencing of the Nuclear DNA of Five Clinical-Grade Human Embryonic Stem Cell Lines
| |
|
| October 10, 2011
| |
|
| BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
| |
|
| October 4, 2011 |
|
|
| BioTime Announces Appointment of Chief Financial Officer
| |
|
| September 29, 2011
| |
|
| BioTime CEO Dr. Michael West to Present at 2011 World Stem Cell Summit at 2:30 p.m. PDT on Monday, October 3, 2011
| |
|
| September 12, 2011
| |
|
| BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2011
| |
|
| September 6, 2011
| |
|
| BioTime Enters into Worldwide License Agreement with Cornell University to Develop and Commercialize Vascular Cells Derived from Human Embryonic Stem Cells
| |
|
| September 1, 2011
| |
|
| BioTime CEO Michael D. West to Present at Rodman & Renshaw 13th Annual Healthcare Conference
| |
|
| August 24, 2011
| |
|
| BioTime's Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing
| |
|
| August 19,2011
| |
|
| BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines
| |
|
| August 9, 2011
| |
|
| BioTime Announces Second Quarter 2011 Financial Results and Corporate Developments
| |
|
| July 21, 2011
| |
|
| BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2011
To View a PDF of the Presentation Click Here
| |
|
| July 19, 2011
| |
|
| BioTime Announces the Issuance of a Second U.S. Glycosan Hydrogel Patent
| |
|
| July 15, 2011
| |
|
| BioTime Receives $335,900 SBIR Grant
| |
|
| June 29, 2011
| |
|
| BioTime Announces Appointment of Chief Commercial Officer
| |
|
| June 27, 2011
| |
|
| BioTime, Inc. Shareholders Meeting 2011 Video
| |
|
| June 9, 2011 |
|
|
| BioTime CEO, Michael D. West, speaks at the Jefferies 2011 Healthcare Conference
| |
|
| June 9, 2011
| |
|
| BioTime Reports First Complete Sequencing of the Nuclear Genome of Five GMP-Compliant Human Embryonic Stem Cell Lines at Jefferies 2011 Global Healthcare Conference
| |
|
| June 3, 2011
| |
|
| BioTime Receives NIH Approval for Two GMP Human Embryonic Stem Cell Lines
| |
|
| June 2, 2011
| |
|
| BioTime CEO Dr. Michael West to Present at the Jefferies 2011 Global Healthcare Conference
| |
|
| May 31, 2011
| |
|
| BioTime's CEO, Michael D. West, speaks to Wall Street Reporter
| |
|
| May 10, 2011
| |
|
| BioTime Announces Issuance of U.S. Glycosan Hydrogel Patent
| |
|
| May 3, 2011
| |
|
| BioTime Initiates Clinical Development Program for HyStem®-Rx as a Cell Delivery Device for Reconstructive Surgery and Other Cell-Based Therapies
| |
|
| April 5, 2011
| |
|
| BioTime and XenneX Form LifeMap Sciences, Inc. to Create Roadmap for Regenerative Medicine
| |
|
| March 22, 2011
| |
|
| BioTime Announces the Closing of the Merger of Glycosan BioSystems with OrthoCyte Corporation
| |
|
| March 15, 2011
| |
|
| BioTime Announces Fourth Quarter and Fiscal Year 2010 Financial Results
and Corporate Developments
| |
|
| February 14, 2011
| |
|
| BioTime Announces Agreement To Acquire Glycosan Biosystems
| |
|
| January 28, 2011
| |
|
| BioTime Acquires Assets of Cell Targeting, Inc.
| |
|
| January 3, 2011
| |
|
| BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders
| |
| |
|
|
